News | Cath Lab | April 19, 2016

Ischemic Postconditioning Shows No Clinical Outcome Improvement for STEMI Patients

Large clinical trial shows no benefit on mortality or hospitalization for heart failure

ischemic postconditioning, STEMI patients, clinical outcomes, ACC.16

April 19, 2016 — A large randomized controlled trial of ischemic postconditioning in patients who had experienced ST-segment elevation myocardial infarction (STEMI) failed to show the procedure significantly reduces death from any cause or hospitalization for heart failure. Data from the trial was presented at the American College of Cardiology’s 65th Annual Scientific Session, April 2-4 in Chicago.

STEMI is a severe form of heart attack caused by prolonged blockage of blood supply in the heart. It requires immediate angioplasty, a non-surgical procedure in which a balloon is fed into the blood vessels through a catheter and inflated to open narrowed or blocked arteries, allowing blood to flow. A stent is often placed at the blockage site to keep the artery open.

In the United States, about 250,000 people experience a STEMI every year.

Ischemic postconditioning is a variation on angioplasty that involves using 30-second bursts of blood flow interspersed with 30-second pauses to restore blood flow to the heart.

“Abrupt reperfusion by angioplasty may itself damage the heart muscle,” said Thomas Engstrøm, M.D., Ph.D., of Rigshospitalet University of Copenhagen, Denmark, and lead author of the study. “The thinking was that performing the reperfusion in a gentle, graded fashion would protect the heart against reperfusion injury.”

Studies suggest that up to 35 percent of patients may experience reperfusion injury during angioplasty, he said.

Earlier studies in STEMI patients showed that ischemic postconditioning improved ST-segment resolution — an important marker of arterial blockage on electrocardiogram — reduced damage to heart muscle, and in some patients limited the extent of reperfusion injury. It was unclear, however, whether these improvements ultimately reduced hospitalizations or improved patient survival.

The DANAMI-3 iPOST trial, which took place in Denmark, included 1,234 patients (average age 61; 79 percent male) with acute STEMI symptoms of less than 12 hours’ duration who were randomly assigned to receive standard angioplasty or ischemic postconditioning prior to stent implantation in the blocked artery. The primary endpoint was a composite of death from any cause and hospitalization for heart failure. Patients were followed for a minimum of two years, with an average follow-up time of 39 months.

Deaths from any cause and hospitalizations for heart failure — the primary endpoint — were reduced by 7 percent in patients who received iPOST compared with those who received standard angioplasty, but this result did not reach statistical significance, Engstrøm said. Although the primary endpoint was not met, a statistically significant 4 percent improvement was seen in a secondary endpoint, left ventricular ejection fraction — a measure of how much blood is being pumped out of the left ventricle — in patients whose STEMIs involved the front wall of the left ventricle (the heart’s main pumping chamber), he said.

“This may translate into improved survival over more years of follow-up,” Engstrøm said.

This study was the first large clinical trial designed to evaluate clinical outcomes in STEMI patients, as opposed to surrogate endpoints such as ST-segment resolution, Engstrøm said. He said larger trials may be required to definitely establish whether ischemic postconditioning improves clinical outcomes.

A limitation of the study is that the physicians performing the angioplasties cannot be blinded to the treatment group that patients are assigned to, Engstrøm said.

The DANAMI-3 iPOST trial was funded by the Danish Agency for Science, Technology and Innovation and Danish Council for Strategic Research.

For more information: www.acc.org

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init